NasdaqCM - Nasdaq Real Time Price USD

Greenwich LifeSciences, Inc. (GLSI)

13.12

+0.78

(+6.32%)

At close: 4:00 PM EDT

11.90

-1.22

(-9.30%)

After hours: 6:46 PM EDT

Insiders are Piling into These 10 Healthcare Stocks in 2024

In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]

Insider Monkey 16 days ago

NVO

LLY

GANX
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 mont

GlobeNewswire last month

GLSI
+6.32%
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa

GlobeNewswire last month

GLSI
+6.32%
Greenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional Shares

Greenwich LifeSciences Inc (NASDAQ:GLSI) has reported an insider purchase by CEO and CFO, 10% Owner Snehal Patel, according to a recent SEC filing.

GuruFocus.com last month

GLSI
+6.32%
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Ital

GlobeNewswire last month

GLSI
+6.32%
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been

GlobeNewswire 2 months ago

GLSI
+6.32%
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the Phase III clinical trial, Flamingo-01. Data Safety Monitoring Board (DSMB) The Flamingo-01 DSMB met twice in 2023 and recommended to continue the study as is

GlobeNewswire 2 months ago

GLSI
+6.32%
We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

GLSI
+6.32%
Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently

Key Insights Greenwich LifeSciences' significant insider ownership suggests inherent interests in company's expansion...

Simply Wall St. 4 months ago

GLSI
+6.32%
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximatel

GlobeNewswire 5 months ago

GLSI
+6.32%
Greenwich LifeSciences Insiders Added US$653.7k Of Stock To Their Holdings

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 5 months ago

GLSI
+6.32%
Insider Buying: Snehal Patel Acquires 1,000 Shares of Greenwich LifeSciences Inc

On September 11, 2023, Snehal Patel, the CEO, CFO, and 10% Owner of Greenwich LifeSciences Inc (NASDAQ:GLSI), purchased 1,000 shares of the company.

GuruFocus.com 7 months ago

GLSI
+6.32%
We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 8 months ago

GLSI
+6.32%

Performance Overview

Return	GLSI	S&P 500
YTD	+24.71%	+6.92%
1-Year	+20.81%	+25.26%
3-Year	-63.99%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Greenwich LifeSciences, Inc. (GLSI)

Insiders are Piling into These 10 Healthcare Stocks in 2024

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Inc (GLSI) CEO and CFO, 10% Owner Snehal Patel Acquires Additional Shares

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

We're Not Very Worried About Greenwich LifeSciences' (NASDAQ:GLSI) Cash Burn Rate

Insiders hold 54% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI), and they've been buying recently

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Insiders Added US$653.7k Of Stock To Their Holdings

Insider Buying: Snehal Patel Acquires 1,000 Shares of Greenwich LifeSciences Inc

We Think Greenwich LifeSciences (NASDAQ:GLSI) Can Afford To Drive Business Growth

Performance Overview